Initiator Pharma initiates toxicology and toxicokinetic studies for its lead drug candidate IPED2015
Initiator Pharma A/S, a Danish Biotech Company developing a novel treatment of Erectile Dysfunction (ED), has initiated its first Good Laboratory Practice (GLP) toxicology and toxicokinetic rat study at Syngene, Bangalore, India. The decision to move forward with the first GLP study was based on the successful completion of preliminary dose range studies in rats and minipigs that as expected showed no critical adverse effect findings affecting the progress of the project. Furthermore, the start of the GLP study is also facilitated by the successful manufacturing of the GLP toxicological